Netherlands-based cultured meat developer Meatable received $47m in series A financing yesterday from investors including DSM Venturing, the corporate venturing arm of health and nutrition product manufacturer Royal DSM.
Section 32, BlueYard Capital, Agronomics, Humboldt and private investors Rick Klausner, Jeffrey Leiden and Taavet Hinrikus also took part in the round.
Meatable is working on laboratory-grown meat that relies on pluripotent cells to replicate the natural process of fat and muscle growth, generating cuts of meat within weeks.
The funding will allow Meatable to advance its small-scale production activities and expand its portfolio. It is currently focusing on pork and beef but its technology is adaptable to any livestock-based food product, including sheep and fish.
The company had previously secured $7m in seed funding from BlueYard Capital and various individual investors in December 2019 alongside a $3m grant from the European Commission’s Eurostars Programme.
BlueYard had already led Meatable’s $3.5m seed round in 2018, participating with Future Positive Capital, Atlantic Food Labs, Backed VC and several angel investors.
The original version of this article appeared on our sister site, Global University Venturing.